Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003

NCT06921486

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Phase IIb:Efsubaglutide Alfa 5 mg QWn/rn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 10 mg QWn/rn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg QWn/rn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg Q2Wn/rn/rn/rn/rn/r
Phase IIb:Placebon/rn/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QWn/rn/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose QWn/rn/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2Wn/rn/rn/rn/rn/r
Phase III:Placebon/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.